SNMMI calls on CMS to cover PET agent Amyvid

02/3/2013 | DOTMed.com

SNMMI and other supporters of the PET imaging agent Amyvid are calling on CMS to provide coverage of the agent for diagnosis of Alzheimer's disease. The move follows a Medicare Evidence Development and Coverage Advisory Committee hearing where the panel questioned the utility of Amyvid in improving health outcomes. SNMMI said clinical evidence and FDA approval of the agent back "the ability of beta-amyloid imaging to change patient management, leading to better outcomes for patients."

View Full Article in:

DOTMed.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Paralegal
Mylan Inc.
Washington, DC
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director of Actuarial Services, Government Programs
PacificSource
Springfield, OR
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC